177 related articles for article (PubMed ID: 12452301)
1. Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndrome: a single center experience.
Ozdemir M; Erdem G; Türkoglu S; Cemri M; Timurkaynak T; Boyaci B; Ridvan Y; Cengel A; Dörtlemez O; Dörtlemez H
Jpn Heart J; 2002 Sep; 43(5):433-42. PubMed ID: 12452301
[TBL] [Abstract][Full Text] [Related]
2. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.
Antman EM; McCabe CH; Gurfinkel EP; Turpie AG; Bernink PJ; Salein D; Bayes De Luna A; Fox K; Lablanche JM; Radley D; Premmereur J; Braunwald E
Circulation; 1999 Oct; 100(15):1593-601. PubMed ID: 10517729
[TBL] [Abstract][Full Text] [Related]
3. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
4. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
Monrad ES
Am J Cardiol; 2000 Apr; 85(8A):2C-9C. PubMed ID: 10793174
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
Kaul S; Shah PK
J Am Coll Cardiol; 2000 Jun; 35(7):1699-712. PubMed ID: 10841215
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
Am J Cardiol; 1998 Sep; 82(5B):19L-24L. PubMed ID: 9737476
[TBL] [Abstract][Full Text] [Related]
7. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
[TBL] [Abstract][Full Text] [Related]
8. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC).
Klein W; Buchwald A; Hillis SE; Monrad S; Sanz G; Turpie AG; van der Meer J; Olaisson E; Undeland S; Ludwig K
Circulation; 1997 Jul; 96(1):61-8. PubMed ID: 9236418
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulants in acute coronary syndromes.
Turpie AG
Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.
Rubboli A; Ottani F; Capecchi A; Brancaleoni R; Galvani M; Swahn E
Cardiology; 2007; 107(2):132-9. PubMed ID: 16864962
[TBL] [Abstract][Full Text] [Related]
11. [Low molecular weight heparins in acute coronary syndrome].
Huber K; Niessner A; Niessner H
Herz; 2001 Apr; 26 Suppl 1():53-60. PubMed ID: 11349628
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
[TBL] [Abstract][Full Text] [Related]
13. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
Ottani F; Ferrini D; Di Pasquale G; Galvani M
Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparins and unstable angina--current perspectives.
Turpie AG
Haemostasis; 1997; 27 Suppl 1():19-24. PubMed ID: 9439754
[TBL] [Abstract][Full Text] [Related]
15. Low molecular weight heparin in acute coronary syndromes.
Cannon CP
Curr Cardiol Rep; 1999 Sep; 1(3):206-11. PubMed ID: 10980843
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
Antman EM; Cohen M; Radley D; McCabe C; Rush J; Premmereur J; Braunwald E
Circulation; 1999 Oct; 100(15):1602-8. PubMed ID: 10517730
[TBL] [Abstract][Full Text] [Related]
17. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
[TBL] [Abstract][Full Text] [Related]
18. [Low molecular weight heparin in unstable angina and myocardial infarction without Q wave].
Choussat R; Montalescot G
Presse Med; 1999 Jun; 28(21):1128-34. PubMed ID: 10399506
[TBL] [Abstract][Full Text] [Related]
19. Therapy of unstable angina with the low molecular weight heparins.
Ageno W; Turpie AG
Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
[TBL] [Abstract][Full Text] [Related]
20. [The safety and efficacy of pre-treatment with enoxaparin (Clexane) in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Hu DY; Zhao XL; Jia SQ; Li TC; Wang L; Zhao H; Kong FL; Chen BX
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):91-3. PubMed ID: 12783703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
